menu
    • menu
    [{"orgOrder":0,"company":"Difgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"||Mu opioid receptor | Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Difgen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Undisclosed"},{"orgOrder":0,"company":"Difgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Difgen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Difgen

    Menu

    Difgen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Difgen

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Difgen

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine Transdermal System From Its US M...

                            Details : Buprenorphine Transdermal System is a partial opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

                            Product Name : Buprenorphine-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : Buprenorphine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Difgen

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Difgen

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buprenorphine Hydrochloride,Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DifGen Pharmaceuticals Completes Successful USFDA Audit of Its US Manufacturing Site Aveva Drug Delivery Syste...

                            Details : Buprenorphine sublingual tablets, is a partial opioid agonist in combination with naloxone, an opioid antagonist, is indicated for the maintenance treatment of opioid dependence.

                            Product Name : Buprenorphine-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Buprenorphine Hydrochloride,Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth